To fully understand the optimal affinity range for promoting affinity-driven tumor selectivity of anti-LYPD1 TCBs, future work should explore anti-LYPD1 Fabs that span a broader affinity range and epitope diversity, since both of these parameters are predicted to influence avidity-driven selectivity and to improve overall potency. The gene discussed is LYPD1; the disease is neoplasm.